BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 28347818)

  • 1. A xenograft model reveals that PU.1 functions as a tumor suppressor for multiple myeloma in vivo.
    Nishimura N; Endo S; Ueno S; Ueno N; Tatetsu H; Hirata S; Hata H; Komohara Y; Takeya M; Mitsuya H; Okuno Y
    Biochem Biophys Res Commun; 2017 May; 486(4):916-922. PubMed ID: 28347818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL.
    Ueno S; Tatetsu H; Hata H; Iino T; Niiro H; Akashi K; Tenen DG; Mitsuya H; Okuno Y
    Oncogene; 2009 Nov; 28(46):4116-25. PubMed ID: 19749795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth.
    Tatetsu H; Ueno S; Hata H; Yamada Y; Takeya M; Mitsuya H; Tenen DG; Okuno Y
    Cancer Res; 2007 Jun; 67(11):5328-36. PubMed ID: 17545613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4.
    Ueno N; Nishimura N; Ueno S; Endo S; Tatetsu H; Hirata S; Hata H; Matsuoka M; Mitsuya H; Okuno Y
    Oncogene; 2017 Aug; 36(31):4481-4497. PubMed ID: 28368411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU.1 up-regulation in myeloma cells.
    Endo S; Amano M; Nishimura N; Ueno N; Ueno S; Yuki H; Fujiwara S; Wada N; Hirata S; Hata H; Mitsuya H; Okuno Y
    Biochem Biophys Res Commun; 2016 Jan; 469(2):236-42. PubMed ID: 26657848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells.
    Yuki H; Ueno S; Tatetsu H; Niiro H; Iino T; Endo S; Kawano Y; Komohara Y; Takeya M; Hata H; Okada S; Watanabe T; Akashi K; Mitsuya H; Okuno Y
    Blood; 2013 Feb; 121(6):962-70. PubMed ID: 23212521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL.
    Romagnoli M; Desplanques G; Maïga S; Legouill S; Dreano M; Bataille R; Barillé-Nion S
    Clin Cancer Res; 2007 Oct; 13(20):6010-8. PubMed ID: 17947462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restoring PU.1 induces apoptosis and modulates viral transactivation via interferon-stimulated genes in primary effusion lymphoma.
    Goto H; Kariya R; Kudo E; Okuno Y; Ueda K; Katano H; Okada S
    Oncogene; 2017 Sep; 36(37):5252-5262. PubMed ID: 28481873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligomerized tumor necrosis factor-related apoptosis inducing ligand strongly induces cell death in myeloma cells, but also activates proinflammatory signaling pathways.
    Berg D; Stühmer T; Siegmund D; Müller N; Giner T; Dittrich-Breiholz O; Kracht M; Bargou R; Wajant H
    FEBS J; 2009 Dec; 276(23):6912-27. PubMed ID: 19895579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
    Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W
    Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PGC1β regulates multiple myeloma tumor growth through LDHA-mediated glycolytic metabolism.
    Zhang H; Li L; Chen Q; Li M; Feng J; Sun Y; Zhao R; Zhu Y; Lv Y; Zhu Z; Huang X; Xie W; Xiang W; Yao P
    Mol Oncol; 2018 Sep; 12(9):1579-1595. PubMed ID: 30051603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Water-Borne Polyurethane Nanomicelles for Cancer Chemotherapy: Higher Efficiency of Folate Receptors Than TRAIL Receptors in a Cancerous Balb/C Mouse Model.
    Ajorlou E; Khosroushahi AY; Yeganeh H
    Pharm Res; 2016 Jun; 33(6):1426-39. PubMed ID: 26908046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calmodulin antagonists induce cell cycle arrest and apoptosis in vitro and inhibit tumor growth in vivo in human multiple myeloma.
    Yokokura S; Yurimoto S; Matsuoka A; Imataki O; Dobashi H; Bandoh S; Matsunaga T
    BMC Cancer; 2014 Nov; 14():882. PubMed ID: 25424011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aloperine executes antitumor effects against multiple myeloma through dual apoptotic mechanisms.
    Wang H; Yang S; Zhou H; Sun M; Du L; Wei M; Luo M; Huang J; Deng H; Feng Y; Huang J; Zhou Y
    J Hematol Oncol; 2015 Mar; 8():26. PubMed ID: 25886453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin inhibits proliferation and induces apoptosis of multiple myeloma cells through regulation of Bcl-2 and Bax and suppression of VEGF.
    Ding JH; Yuan LY; Huang RB; Chen GA
    Eur J Haematol; 2014 Oct; 93(4):329-39. PubMed ID: 24766194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
    Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
    Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor suppressor XIAP-Associated factor 1 (XAF1) cooperates with tumor necrosis factor-related apoptosis-inducing ligand to suppress colon cancer growth and trigger tumor regression.
    Tu SP; Sun YW; Cui JT; Zou B; Lin MC; Gu Q; Jiang SH; Kung HF; Korneluk RG; Wong BC
    Cancer; 2010 Mar; 116(5):1252-63. PubMed ID: 20082449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo.
    Ge NL; Rudikoff S
    Oncogene; 2000 Aug; 19(36):4091-5. PubMed ID: 10962569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cooperation of Spi-1/PU.1 with an activated erythropoietin receptor inhibits apoptosis and Epo-dependent differentiation in primary erythroblasts and induces their Kit ligand-dependent proliferation.
    Quang CT; Wessely O; Pironin M; Beug H; Ghysdael J
    EMBO J; 1997 Sep; 16(18):5639-53. PubMed ID: 9312023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The imbalance between Survivin and Bim mediates tumour growth and correlates with poor survival in patients with multiple myeloma.
    Romagnoli M; Séveno C; Wuillème-Toumi S; Amiot M; Bataille R; Minvielle S; Barillé-Nion S
    Br J Haematol; 2009 Apr; 145(2):180-9. PubMed ID: 19298592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.